# Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer

> **NCT02147990** · PHASE2 · TERMINATED · sponsor: **Clovis Oncology, Inc.** · enrollment: 318 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Rociletinib

## Key facts

- **NCT ID:** NCT02147990
- **Lead sponsor:** Clovis Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-06-16
- **Primary completion:** 2019-07-30
- **Final completion:** 2019-08-27
- **Target enrollment:** 318 (ACTUAL)
- **Why stopped:** Sponsor discontinued development of CO-1686 for NSCLC.
- **Last updated:** 2020-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02147990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02147990, "Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02147990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*